Sorry, I meant to say the branded product, Lovenox. Is this possibility perhaps factored into the recent share price?
With my feeble brain, I'm having trouble following all the discussions about MNTA here. A question I have is why doesn't SNY just lower the cost of their drug--14% doesn't seem like such a horrendouos discount--in order to retain market share, or even lower their drug pricing below Sandoz's, in order to drive Sandoz's generic out of the market?
If I were a SNY rep, I'd be saying something like, "Look, we'll give you the same price as Sandoz is charging and you won't be risking the lives of your patients with a drug that has never gone through clinical testing."
Bladerunner
Market Data 
Markets 
AI
